Core Insights - Niagen Bioscience has partnered with OneSpaWorld to offer Niagen IV at over 80 Medi-Spa clinics on high-end cruise ships, marking its first cruise ship clinic partnership [1][2] - This collaboration aims to expand Niagen Plus' presence and provide premium wellness experiences to vacationing consumers [2][3] Company Overview - Niagen Bioscience, Inc. is a leader in NAD+ science and healthy aging research, focusing on innovative NAD+-boosting solutions [6][9] - The company has developed a next-generation intravenous formulation of pharmaceutical-grade Niagen, designed to enhance cellular vitality and support healthy aging [3][9] Product Details - Niagen IV is a 500 mg intravenous solution that offers a better patient experience with 75% shorter infusion times and a quicker rise in NAD+ blood levels compared to traditional NAD+ IV [3][5] - The product is compounded and distributed by FDA-registered outsourcing facilities, ensuring high safety and quality standards [9][5] Market Expansion - The partnership with OneSpaWorld opens a new premium channel for Niagen IV, enhancing the company's clinical footprint, which already includes over 1,200 wellness clinics across the U.S. [2][5] - OneSpaWorld operates health and wellness services on 208 cruise ships, providing a significant opportunity for Niagen Bioscience to reach new consumers [10][5] Strategic Goals - The collaboration supports Niagen Bioscience's strategy to scale its offerings outside the U.S. and tap into the growing demand for wellness services among travelers [2][3] - The company continues to broaden its intellectual property portfolio, recently securing a patent for the methods of use of Niagen in IV and injectable formulations [3][10]

Core Viewpoint - Niagen Bioscience, Inc. will participate in the 38th Annual ROTH Conference, focusing on healthy aging and NAD+ science, with key presentations and meetings scheduled for March 22-24, 2026 [1][2]. Company Overview - Niagen Bioscience, Inc. is recognized as the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy aging research, dedicated to advancing healthspan through innovative NAD+-boosting solutions [4][5]. - The company’s product portfolio includes Niagen®, a patented nicotinamide riboside (NR), which is the most efficient and well-researched NAD+ booster available [7]. Conference Participation - CEO Rob Fried will participate in the Technologies Advancing Healthy Aging Panel on March 23, 2026, at 2:00 PM PT, which will be livestreamed [2][4]. - The conference will feature one-on-one and small-group meetings, analyst-selected fireside chats, and industry keynotes, with participation from executive management of numerous companies [3]. Research and Development - Niagen Bioscience has established over 300 external research agreements with global institutions, contributing to 45 published clinical studies, marking a significant milestone in NAD+ research support [12]. - The company collaborates with renowned scientists and research institutions to explore the potential of NAD+, which is crucial for cellular function and declines with age [5][6]. Financial Performance - In fiscal year 2025, Niagen Bioscience reported a 30% year-over-year increase in net sales, reaching $129.4 million, and a 103% increase in net income to $17.4 million [14]. - The fourth quarter of 2025 saw total net sales increase by 16% to $33.8 million, with Tru Niagen® sales rising by 21% to $27.5 million [15].

Core Insights - Niagen Bioscience has announced the sale of its ChromaDex Reference Standards business to LGC in an all-cash transaction, aimed at streamlining operations and focusing on core activities related to NAD+ science and healthy aging [1] Company Strategy - The divestiture is part of Niagen Bioscience's strategy to exit non-core activities and allocate resources towards NAD+ science, intellectual property, and commercial growth within the longevity industry [1] - CEO Rob Fried emphasized that this transaction allows the company to focus on advancing NAD+ science and delivering patented Niagen® solutions [1] Acquisition Details - The sale to LGC is expected to enhance LGC's capabilities in supporting pharmaceutical customers, testing laboratories, and food producers by expanding their reference materials and analytical standards portfolio [1] - LGC Standards, a division of LGC Group, is recognized as a global leader in life sciences and analytical solutions [1] Market Position - Niagen Bioscience is positioned as a leader in NAD+ science and healthy aging research, with a focus on innovative NAD+-boosting solutions [1] - The company’s flagship product, Niagen®, is noted as the most efficient and well-researched NAD+ booster available [1] Future Outlook - Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative solutions, with a robust patent portfolio protecting its NAD+ precursors [1]

Core Insights - Niagen Bioscience, Inc. (NASDAQ: NAGE) is recognized as a global authority on NAD+ with a focus on healthy aging science [1] - The company has expanded the availability of its pharmaceutical-grade Niagen Plus™ products, including Niagen IV and injections, to over 50 iCRYO locations across the U.S., increasing access to more than 900 clinics nationwide [1] Company Developments - The partnership with iCRYO enhances the distribution of Niagen Bioscience's innovative and science-backed NAD+ boosting products [1]